GlaxoSmithKline PLC (NYSE:GSK) was downgraded by equities researchers at TheStreet from a “b” rating to a “c+” rating in a research note issued to investors on Wednesday.
Several other equities research analysts have also recently weighed in on the stock. Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Finally, ValuEngine cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. GlaxoSmithKline PLC has a consensus rating of “Hold” and a consensus price target of $46.00.
Shares of GlaxoSmithKline PLC (NYSE:GSK) traded up 0.44% during trading on Wednesday, hitting $40.93. 6,233,161 shares of the stock traded hands. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $45.58. The firm has a market capitalization of $99.99 billion, a price-to-earnings ratio of 45.78 and a beta of 1.04. The firm has a 50-day moving average of $42.84 and a 200-day moving average of $41.78.
GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. The company had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. On average, equities analysts forecast that GlaxoSmithKline PLC will post $2.84 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2017/07/28/thestreet-lowers-glaxosmithkline-plc-nysegsk-to-c.html.
A number of large investors have recently bought and sold shares of GSK. Carroll Financial Associates Inc. raised its position in GlaxoSmithKline PLC by 0.4% in the second quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock worth $374,000 after buying an additional 35 shares during the period. First National Bank of Omaha raised its position in GlaxoSmithKline PLC by 0.3% in the second quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock worth $827,000 after buying an additional 57 shares during the period. Pekin Singer Strauss Asset Management IL raised its position in GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock worth $233,000 after buying an additional 60 shares during the period. Baystate Wealth Management LLC raised its position in GlaxoSmithKline PLC by 1.4% in the second quarter. Baystate Wealth Management LLC now owns 5,520 shares of the pharmaceutical company’s stock worth $233,000 after buying an additional 75 shares during the period. Finally, Investment Partners Ltd. OH ADV raised its position in GlaxoSmithKline PLC by 0.8% in the second quarter. Investment Partners Ltd. OH ADV now owns 9,491 shares of the pharmaceutical company’s stock worth $409,000 after buying an additional 76 shares during the period. Institutional investors and hedge funds own 8.98% of the company’s stock.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
